Top Markets
#1 QuantixAI QuantixAI +102.94%
#2 Pons Pons +35.47%
#3 龙虾 (Lobster) 龙虾 (Lobster) +30.81%
#4 Rain Rain +30.63%
#5 MetaDAO MetaDAO +27.10%
#6 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +21.74%
#7 Bedrock Bedrock +20.16%
#8 Prom Prom +17.45%
#9 Ontology Gas Ontology Gas +15.41%
#10 peaq peaq +15.03%
Coin of the day
QuantixAI QuantixAI
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Heidelberg Pharma AG Heidelberg Pharma AG

Heidelberg Pharma AG

HPHA
Classement en actions #20133
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a... Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
Prix de l'action
$2.99
Capitalisation boursière
$139.84M
Changement (1 jour)
-0.40%
Changement (1 an)
-41.27%
Pays
DE
Échange Heidelberg Pharma AG (HPHA)

Catégorie

Healthcare
Le prix HPHA avec la capitalisation boursière de B
Heidelberg Pharma AG Heidelberg Pharma AG
HPHA
$2.99
Capitalisation boursière de Heidelberg Pharma AG(HPHA)
Capitalisation boursière: $139.84M
En August 2026, Heidelberg Pharma AG a une capitalisation boursière de $139.84M. Cela fait de Heidelberg Pharma AG la 20133rd entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Heidelberg Pharma AG du 2006 au 2026
HPHA par rapport au top 5 des plus populaires stocks
Prix pour HPHA L’actif B La capitalisation boursière de B Résultats
Heidelberg Pharma AG Heidelberg Pharma AG
$110,133 $139.84M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.152T +3,684,359.38%
Heidelberg Pharma AG Heidelberg Pharma AG
$96,977.21 $139.84M
Apple Inc. Apple Inc.
AAPL
$4.537T +3,244,249.43%
Heidelberg Pharma AG Heidelberg Pharma AG
$88,987.54 $139.84M
Alphabet Inc. Alphabet Inc.
GOOG
$4.163T +2,976,957.06%
Heidelberg Pharma AG Heidelberg Pharma AG
$77,853.95 $139.84M
Microsoft Corporation Microsoft Corporation
MSFT
$3.642T +2,604,485.26%
Heidelberg Pharma AG Heidelberg Pharma AG
$59,949.55 $139.84M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.805T +2,005,497.91%